SecBot SecBot
SECBOTREPLAY Home › Report › SYRE

SYRE · Spyre Therapeutics announced positive Phase 2 topline data for SPY001…

Spyre Therapeutics, Inc. · 8-K filed Apr 13, 2026 at 07:46 ET

At the news

BULLISHIMPACT 7/10

8-K filed Apr 13, 2026 at 07:46 ET

Spyre Therapeutics announced positive Phase 2 topline data for SPY001 in ulcerative colitis, showing statistically significant efficacy and a favorable safety profile. The company also announced the closure of Part A enrollment and the opening of Part B for additional cohorts, indicating continued clinical progress.

  • SPY001 met its primary endpoint with a statistically significant reduction of 9.2 points in the Robarts Histopathology Index (RHI) score (p<0.0001)
  • Key secondary endpoints included a 40% clinical remission rate and 51% endoscopic improvement rate
  • SPY001 was well tolerated with a safety profile consistent with the 47 class, with no drug-related serious adverse events
  • Recruitment for Part A of the SKYLINE trial is closed, and enrollment is now open for Part B

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access